FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR Ahead of key Competitiveness Council Meeting of European Research Ministers, ESMO calls for measures supporting a robust clinical research ecosystem in Europe that enables... EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context MOST POPULAR Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib... August 21, 2025 Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer March 31, 2026 Cancer in My Community: Expanding Genetic Testing in Thailand October 11, 2022 Load more HOT NEWS Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... Surprise! Financial Assistance To Help With Your Medical Bills May Be... Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant...
